Nuevocor Closes US$45 Million Series B Financing for Clinical Development of Novel Mechanobiology-Centered Therapy for Cardiomyopathy

Nuevocor, a Singapore-headquartered IND-stage biotechnology company, has successfully completed a US$45 million Series B financing round co-led by Kurma Partners and Angelini Ventures, with participation from existing investors EDBI, ClavystBio, Boehringer Ingelheim Venture Fund, Highlight Capital, and SEEDS Capital. The funds will support a Phase 1/2 clinical trial of lead candidate NVC-001 for LMNA-related dilated cardiomyopathy.